Kamat Pharmatech
A New Jersey–based contract development organization (CDO) providing formulation, process development, regulatory strategy, and commercialization support for complex injectables, oral liquids, ophthalmics, and topical/semi-solid products. Operates R&D and client-facing services with experience in lyophilization, sterile/aseptic processes, and 505(b)(2) development.
Industries
Nr. of Employees
small (1-50)
Kamat Pharmatech
Products
Nystatin oral suspension (launched)
Oral suspension formulation of nystatin that the company reports launched with market uptake in the US.
Trazodone oral solution (505(b)(2) product launched)
A trazodone oral solution launched via a 505(b)(2) pathway reported by the company.
Nystatin oral suspension (launched)
Oral suspension formulation of nystatin that the company reports launched with market uptake in the US.
Trazodone oral solution (505(b)(2) product launched)
A trazodone oral solution launched via a 505(b)(2) pathway reported by the company.
Services
Formulation and development services for sterile injectable dosage forms including lyophiles, suspensions, liposomes, emulsions, and microspheres.
Product and process development for lyophilized dosage forms and related technical training.
Development support for complex generic products, including formulation, characterization, and regulatory planning.
Development of unique oral liquid formulations and associated characterization.
Formulation and IVRT characterization services for topical and semi-solid products.
Support for 505(b)(2) regulatory pathways and related development planning.
Formulation and development services for sterile injectable dosage forms including lyophiles, suspensions, liposomes, emulsions, and microspheres.
Product and process development for lyophilized dosage forms and related technical training.
Development support for complex generic products, including formulation, characterization, and regulatory planning.
Development of unique oral liquid formulations and associated characterization.
Formulation and IVRT characterization services for topical and semi-solid products.
Support for 505(b)(2) regulatory pathways and related development planning.
Expertise Areas
- Complex injectable development
- Lyophilization and freeze-drying
- Formulation development (oral liquids, topicals, ophthalmics)
- Aseptic and sterile processing
Key Technologies
- Lyophilization (freeze-drying)
- Nano-suspension technology
- Aseptic processing
- Liposome and emulsion formulation
News & Updates
Successful launch and reported significant US market share for a nystatin oral suspension product.
Reported launch of a trazodone oral solution developed and commercialized using a 505(b)(2) regulatory pathway.
Company reports gearing to file and launch five unique products within 1-2 years.
Successful launch and reported significant US market share for a nystatin oral suspension product.
Reported launch of a trazodone oral solution developed and commercialized using a 505(b)(2) regulatory pathway.
Company reports gearing to file and launch five unique products within 1-2 years.